Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 269 participants.

Also called NCT03565913

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 269 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03565913
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03565913. Randomized; quadruple masking; primary purpose treatment. Start 2017-01-22 (actual); primary completion 2026-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V
Condition
CKD Stage 5
Intervention (Drug)
EffCaMgCit
Intervention (Other)
CaAcS
Lead sponsor
University of Texas Southwestern Medical Center (class: other)

Record details

Record id
cardio:ct-nct03565913
Content hash
d9f094cf29e218a2bc276496f9fcf1927a89de93fb19fb85ec99e0264c318570